Marker Therapeutics Inc (MRKR)

[microcapbiotech]

OK, It's 2022. Hope all had a great Holiday season.
As we all look forward toward better things, I have a question for those who understand this stuff better than me ... and it concerns a question that I asked Phantom, that he forwarded to Marker.

OK, the subject is Tumor Associated Antigens.
WE (MRKR) use 5 in our cocktail mix.
PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1.
Now I assume those 5 were chosen after some reseach and determination that those 5 would be the most effective against AML.

I read this on tumor markers: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list

BOY, there sure is a lot of them for a whole bunch of different cancers, with different markers for different cancers.

And I read this: "The National Cancer Institute has recently published a priority list of 75 cancer antigens, providing a useful basis for those aiming to test vaccine design and operation against well-documented targets."

And then I read this ... of which ... OUR OWN DR. ALLISON was a part of: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779623/

So my question is this.
Is using the same 5 antigens (PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1) on cancers that are not AML still be substantially effective?

We know/assume they are great antigens for AML, but does ANYBODY KNOW they are good antigen targets for ... let's say, Pancreatic, or different blood/bone/brain/etc. cancers?

Or, would a different, more targeted antigen cocktail mix be better?

Anybody have an idea about what BOTH, the added time and the added money would be to research which 5 antigens (out of the 75) would be most effective against Pancreatic (the same kind of research they did to chose the 5 for AML)?

I don't want to intentionally oversimplify the complex FDA preclinical process but, you put some Pancreatic cancer cells in a glass dish, you introduce 1 of the 75 antigens, you see what happens, and then you do that with the other 74.
How long and expensive could that be?

Thank You All, let's have a better 2022.